ReviewMarine drugs2023
Marine-Derived Components: Can They Be a Potential Therapeutic Approach to Parkinson's Disease?
Review in Marine drugs, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- Algal polysaccharides: new perspectives for the treatment of basal ganglia neurodegenerative diseases.Frontiers in neuroanatomy · 2024Pooled it
- Nanotechnological applications of marine algae derived neurotoxins spanning harmful algal blooms and therapeutic innovations.Discover nano · 2026Review
- Review
- Marine bacterium Stutzerimonas stutzeri mitigates Parkinson's disease pathology in C. elegans via ferroptosis modulation.Scientific reports · 2026Article
- Chemical Characterization and Bio-Screening of Neuroprotective Potential of Brazilian Brown SeaweedAntioxidants (Basel, Switzerland) · 2025Article
- Marine Bioactive Components and Chronic Neuroinflammation: Focus on Neurodegenerative Disease.Marine drugs · 2025Review
- Therapeutic Convergence in Neurodegeneration: Natural Products, Drug Repurposing, and Biomolecular Targets.Biomolecules · 2025Article
- Integrating Blood Biomarkers and Marine Brown Algae-Derived Inhibitors in Parkinson's Disease: A Multi-scale Approach from Interactomics to Quantum Mechanics.Molecular biotechnology · 2025Article
- Increasing Life Expectancy with Plant Polyphenols: Lessons from the Mediterranean and Japanese Diets.Molecules (Basel, Switzerland) · 2025Review
- Marine Natural Products as Anticancer Agents 3.0.Marine drugs · 2025Article
- Neuroprotective and Anti-Inflammatory Activity ofMarine drugs · 2025Article
- Deep-Sea-Derived Isobisvertinol Targets TLR4 to Exhibit Neuroprotective Activity via Anti-Inflammatory and Ferroptosis-Inhibitory Effects.Marine drugs · 2025Article
- Natural products in neurodegenerative diseases: recent advances and future outlook.Frontiers in pharmacology · 2025Review
- Editorial: Natural products as drivers in drug development for neurodegenerative disorders, volume II.Frontiers in pharmacology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
Abstract
The increase in the life expectancy average has led to a growing elderly population, thus leading to a prevalence of neurodegenerative disorders, such as Parkinson's disease (PD). PD is the second most common neurodegenerative disorder and is characterized by a progressive degeneration of the dopaminergic neurons in the substantia
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.